Subjective Sleep Quality in Amnestic Mild Cognitive Impairment Elderly and Its Possible Relationship With Plasma Amyloid-β

Yajing Liu, Lushi Chen, Shuyun Huang, Chengguo Zhang, Zeping Lv, Jiali Luo, Pan Shang, Yu–Kai Wang, Haiqun XieFrontiers in Neuroscience 2020 · DOI

Abstract

Poor sleep quality was associated with plasma Aβ<sub>42</sub> and Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio, with a stronger effect among individuals with aMCI. A better understanding of the role of sleep in plasma Aβ levels in aMCI patients could lead to effective sleep-based intervention against the risk of Alzheimer's disease.

Introduction

Alzheimer’s Disease (AD) is characterized by the accumulation of Amyloid-β (Aβ) plaques in the brain. Recent neuroscience has highlighted the "glymphatic system," a waste-clearance mechanism that flushes metabolic byproducts like Aβ from the brain primarily during deep sleep. While the link between sleep deprivation and Aβ buildup in cerebrospinal fluid (CSF) is well-documented, CSF collection is invasive and PET imaging is expensive.

This study sought to determine if subjective sleep quality (how a person feels they are sleeping) correlates with plasma Aβ levels—a much more accessible blood-based biomarker. Specifically, the researchers focused on individuals with amnestic Mild Cognitive Impairment (aMCI), a clinical stage where memory loss is present but daily function remains intact, as these individuals are at the highest risk of progressing to Alzheimer’s.

Methods

The study involved a cross-sectional analysis of 305 elderly participants (133 with aMCI and 172 cognitively normal controls) recruited from Cognitive Disorders Clinics and community volunteers in Foshan, China.

  • Sleep Assessment: Participants completed the Pittsburgh Sleep Quality Index (PSQI), covering seven domains: quality, latency, duration, efficiency, disturbances, medication use, and daytime dysfunction. Higher scores indicate worse sleep.
  • Biomarker Analysis: Plasma levels of Aβ40 and Aβ42 were measured using sandwich enzyme-linked immunosorbent assay (ELISA) techniques. The ratio of Aβ42/Aβ40 was also calculated, as it is often a more sensitive predictor of brain amyloid burden.
  • Statistical Modeling: Multivariable linear regression was used to find associations, adjusting for age, gender, APOE ε4 status, BMI, education, and comorbidities.

Key Results

Disparities in Sleep Quality

The aMCI group demonstrated significantly poorer sleep quality across nearly all measured domains compared to the cognitively normal (NC) group. The aMCI group had significantly higher global PSQI scores (8.72 ± 3.87) than the NC group (7.10 ± 3.07, p < 0.001). Specific deficits were noted in sleep latency (the time taken to fall asleep), overall duration, and sleep efficiency.

Comparison of sleep variables and PSQI scores between cognitively normal (NC) and amnestic mild cognitive impairment (aMCI) groups.

Correlation with Plasma Biomarkers

The most striking insight was that the link between poor sleep and Aβ levels was not uniform across groups.

  • Aβ42 Correlation: In the aMCI group, higher PSQI scores (worse sleep) were positively associated with plasma Aβ42 levels (β = 0.063, p = 0.049). This association was not significant in the cognitively normal group.
  • The Aβ42/Aβ40 Ratio: A higher PSQI score was associated with a higher Aβ42/Aβ40 ratio in both groups, but the association was much more robust in the aMCI group (β = 0.076 vs. β = 0.030, p for interaction = 0.023).
Multivariable linear regression models showing the association between sleep quality (PSQI) and plasma Aβ levels in NC and aMCI cohorts.

These associations remained significant even after adjusting for the APOE ε4 genotype and other lifestyle factors, suggesting sleep is an independent contributor to Aβ levels.

Discussion

The findings suggest that as the brain begins to decline cognitively, it may become more sensitive to the "trash-clearing" failures caused by poor sleep. This study reinforces the growing consensus that blood-based biomarkers can reflect neurodegenerative processes. Because Aβ peptides move dynamically between the brain and periphery, plasma levels can serve as a cost-effective proxy for what is happening behind the blood-brain barrier.

Limitations and Future Work

The authors acknowledge several limitations, including the subjective nature of the PSQI and the cross-sectional design, which cannot establish causation. It remains a "chicken or egg" problem: does poor sleep cause Aβ accumulation, or does Aβ accumulation disrupt the brain's sleep-regulating circuits? Future longitudinal studies should investigate whether improving sleep quality through clinical intervention can slow the progression of aMCI to Alzheimer’s Disease.

Summary updated

Abstract

Poor sleep quality was associated with plasma Aβ<sub>42</sub> and Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio, with a stronger effect among individuals with aMCI. A better understanding of the role of sleep in plasma Aβ levels in aMCI patients could lead to effective sleep-based intervention against the risk of Alzheimer's disease.
BibTeX
@inproceedings{liu2020subjective,
  author = {Yajing Liu and Lushi Chen and Shuyun Huang and Chengguo Zhang and Zeping Lv and Jiali Luo and Pan Shang and Yu–Kai Wang and Haiqun Xie},
  title = {{Subjective Sleep Quality in Amnestic Mild Cognitive Impairment Elderly and Its Possible Relationship With Plasma Amyloid-β}},
  booktitle = {Frontiers in Neuroscience},
  year = {2020},
  doi = {10.3389/fnins.2020.611432},
}
Figure